Daily market recaps with key events, stock movements, and global influences 14 posts • GPT (4.1 mini) Updated May 17, 2025, 11:17 AM The 2025 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress and related oncology conferences have highlighted several advancements in cancer treatment and diagnostics.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Orca-T Improves Survival
FDA Approves Telisotuzumab Vedotin for NSCLC; Merck's KEYNOTE-B96 Meets PFS Endpoint in Ovarian Cancer; Nivolumab/Ipilimumab, Retifanlimab, Zanidatamab, and Bristol Myers Squibb Gain Approvals | DeepNewz Health
Daily market recaps with key events, stock movements, and global influences 11 posts • GPT (4.1 mini) Published May 17, 2025, 07:56 AM The 2025 medical oncology landscape has seen multiple advancements and regulatory approvals across various cancer types.
FDA Approves Merck’s WELIREG® for PPGL; AbbVie, Bristol Myers Squibb, and EU Commission Gain Lung Cancer Approvals
Daily market recaps with key events, stock movements, and global influences 10 posts • GPT (4.1 mini) Updated May 16, 2025, 09:13 PM The U.S. Food and Drug Administration (FDA) has approved Merck's WELIREG® (belzutifan) for the treatment of adults and pediatric patients aged 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL), rare types of adrenal gland tumors. This marks the first oral therapy approved for these conditions.
FDA Approves Merck’s Belzutifan for PPGL, AbbVie’s Emrelis for NSCLC, Incyte’s Zynyz for Anal Cancer, and Multiple Other Cancer Therapies
Daily market recaps with key events, stock movements, and global influences 10 posts • GPT (4.1 mini) Updated May 16, 2025, 05:39 AM The U.S. Food and Drug Administration (FDA) has approved several new cancer therapies, expanding treatment options across multiple cancer types. Merck's WELIREG® (belzutifan) received approval for adults and pediatric patients aged 12 and older with locally advanced, unresectable, or metastatic pheochromocytoma and paraganglioma (PPGL).
Ubrogepant 100 mg, Oveporexton, and Pembrolizumab Regimens Show Benefit in Migraine, Narcolepsy, and Ovarian Cancer Trials
Daily market recaps with key events, stock movements, and global influences 17 posts • GPT (4.1) Published May 15, 2025, 05:32 PM Recent clinical research has reported advances in the treatment of migraine, narcolepsy type 1, and platinum-resistant ovarian cancer.
Partner Trial: Olaparib Before Surgery Achieves 100% Three-Year Survival in BRCA-Mutated Breast Cancer (39 vs 45 Patients)
12 posts • GPT (4.1) Published May 15, 2025, 09:08 AM A clinical trial led by Addenbrooke's Hospital in Cambridge, known as the Partner trial and published in Nature Communications, evaluated the use of olaparib, a PARP inhibitor, before surgery in women with early-stage, aggressive, inherited breast cancer carrying BRCA1 or BRCA2 mutations.
Roche’s Perjeta Cuts Death Risk 17% in HER2-Positive Breast Cancer; T-DXd, HER2 ADC, and New Surgical Method Show Promise
American Institute for Cancer Research @aicrtweets NEW BLOG! Precision oncology is a cancer treatment approach that tailors therapies to a patient’s genetic makeup. The hope is that precision oncology will provide more effective and targeted treatments.
CAR T-Cell Advances, $25.6M Funding, and OVATION-3 Trial Highlight New Cancer Therapy Breakthroughs
Daily market recaps with key events, stock movements, and global influences 11 posts • GPT (4.1 mini) Published May 14, 2025, 02:48 AM Recent developments in cancer treatment highlight promising advances beyond traditional chemotherapy. Targeted CAR T-cell therapies have shown early efficacy in treating solid tumors and relapsed/refractory multiple myeloma, with efforts underway to mitigate associated brain inflammation and cognitive deficits observed in preclinical models.
Merck to Present New Research on 25 Cancer Types, Including KEYTRUDA and WELIREG, at ASCO 2025
Daily market recaps with key events, stock movements, and global influences 13 posts • Grok (2) Published May 13, 2025, 09:38 PM Merck & Co., Inc. will showcase new research spanning more than 25 types of cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting in 2025. The company's broad and differentiated oncology portfolio and pipeline will be highlighted, focusing on novel treatment approaches and scientific advances.
CRISPR-Edited Allogeneic CD19 CAR-T Achieves 100% Remission in Refractory SLE Amid Advances in Cancer Therapy
5 posts • GPT (4.1 mini) Published May 13, 2025, 06:41 PM Recent developments in immunotherapy highlight promising advances in treating autoimmune diseases and cancer. A novel approach to autoimmune disorders, particularly systemic lupus erythematosus (SLE), has emerged with the potential to reset the immune system rather than merely suppress it. A small trial in 2022 suggested this paradigm shift, and new data from Zhejiang University reinforce these findings.
CytomX's CX-2051 Shows 28% Response Rate in CRC, Raises $100M with 76.9M Shares
36 posts âą Grok (2) Published May 13, 2025, 12:05 AM CytomX Therapeutics Inc. has announced positive interim data from a Phase 1 dose escalation study of its EpCAM-targeting antibody drug conjugate, CX-2051, in patients with advanced colorectal cancer (CRC). The study, which aims to enroll 124 subjects across various tumor types, reported a 28% confirmed response rate among patients treated with doses of 7.2mg/kg, 8.6mg/kg, or 10.0mg/kg, with a 43% response rate at the 10 mg/kg dose.
FDA Approves Verastem Ovarian Cancer Therapy, Clears Lantern Pharma Phase 1b/2 LP-184 Trial for NSCLC
8 posts • GPT (4.1 mini) Published May 12, 2025, 01:51 PM The Food and Drug Administration (FDA) has granted accelerated approval to Verastem Oncology's combination therapy for adults previously treated for a rare form of ovarian cancer. Additionally, the FDA cleared Lantern Pharma to initiate a Phase 1b/2 clinical trial of LP-184 for patients with treatment-resistant non-small cell lung cancer (NSCLC) characterized by high unmet medical need.
University of Minnesota Advances Immunoablative Therapy Eliminating Cancer in 80%, FDA Approves Dostarlimabe-Based Ovarian Cancer Treatment
Daily market recaps with key events, stock movements, and global influences 10 posts • GPT (4.1 mini) Updated May 12, 2025, 05:32 AM A novel immunoablative therapy has demonstrated promising results in eliminating cancer in approximately 80% of patients with a specific genetic mutation, according to a study involving 103 participants.
Dostarlimab, PRL3-zumab, and Gene-Editing Therapies Show Cancer Elimination and Reduced Surgery in Multiple Trials
4 posts • GPT (4.1 mini) Published May 11, 2025, 05:18 PM Recent advancements in cancer immunotherapy have demonstrated promising results across multiple studies and trials. A study involving dostarlimab, an immunotherapy antibody, showed cancer elimination in 80% of patients with a specific genetic mutation, with 84 out of 103 patients responding positively.
Corvus Pharmaceuticals Reports 63% EASI-75 Response in Phase 1 Soquelitinib Trial, Stock Up 31%
Daily market recaps with key events, stock movements, and global influences 6 posts • GPT (4.1 mini) Updated May 10, 2025, 02:29 PM Corvus Pharmaceuticals Inc. (CRVS) announced data from cohorts 1-3 of its placebo-controlled Phase 1 clinical trial evaluating soquelitinib, an oral treatment for atopic dermatitis (AD).
Corvus Pharmaceuticals Reports Phase 1 Data Showing 63% EASI-75 Response and Safety for Oral Soquelitinib in Atopic Dermatitis
4 posts ⢠GPT (4.1 mini) Published May 9, 2025, 01:04 AM Corvus Pharmaceuticals (ticker: CRVS) announced data from cohorts 1 to 3 of its placebo-controlled Phase 1 clinical trial evaluating Soquelitinib, an oral treatment for atopic dermatitis. The trial included patients with varying severity, including those who had failed prior treatments such as Dupilumab (DUPI) and Janus kinase (JAK) inhibitors.
Dostarlimab Enables Surgery-Free Treatment in Rectal Cancer; New Immunotherapy Targets 15 Cancers Amid Rising Early-Onset Colorectal Cases
Daily market recaps with key events, stock movements, and global influences 16 posts • GPT (4.1 mini) Updated May 4, 2025, 08:42 AM A recent study published in the New England Journal of Medicine highlights that the immunotherapy drug dostarlimab has shown promising results in treating early-stage cancers, enabling some patients to avoid surgery entirely. In a trial involving 49 rectal cancer patients treated with dostarlimab for six months, tumors disappeared completely.
Durvalumab and Tarlatamab Improve Survival in SCLC; FDA Grants Fast Track to ISB 2001 and Givinostat; EU Approves Glofitamab
Daily market recaps with key events, stock movements, and global influences #GileadNews: We’re presenting new ASSURE data at #EASLCongress that show results for people with primary biliary cholangitis (PBC) who had prior use of existing therapies.
4 posts • GPT (4.1 mini) Published May 7, 2025, 03:47 AM iBio Inc. announced that its first-in-class Activin E antibody achieved over 26% fat reduction without muscle loss in a preclinical model. The antibody demonstrated a strong synergistic effect when combined with GLP-1 receptor agonists, resulting in a 77% reduction in fat mass.
Pfizer's Sasanlimab and BCG Combination Reduces Bladder Cancer Risk by 32% in Phase 3 CREST Trial
14 posts • Grok (2) Updated Apr 27, 2025, 01:42 AM Pfizer Inc. has announced significant results from the pivotal Phase 3 CREST trial, showing that sasanlimab, an investigational anti-PD-1 monoclonal antibody, in combination with standard Bacillus Calmette-Guérin (BCG) therapy, significantly improves event-free survival (EFS) in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC).
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Orca-T Improves
Contact Orca-T Improves, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack